Expression of miR-155 and miR-146a in Skin Tissue, Peripheral Blood Mononuclear Cells and Serum of Patients with Psoriasis and Its Clinical Significance

Objective: To explore the expression and clinical significance of miR-155 and miR-146a in psoriasis patients from different sources. Methods: The expression levels of miR-155 and miR-146a in psoriasis vulgaris tissues, peripheral blood mononuclear cells, and serum were detected by the QRT-PCR method in 30 patients with psoriasis vulgaris and 30 healthy subjects as the normal control group, and the correlation between the expression levels of miR-155 and miR-146a in psoriasis samples from different sources was analyzed. And the expression levels of miR-155 and miR-146a in peripheral blood mononuclear cells, and serum after treatment. Results: The expression of miR-155 and miR-146a in skin tissue, peripheral blood mononuclear cells and serum of patients with psoriasis was significantly higher than that of normal controls (P < 0.01). miR-155 and miR-146a were highly expressed in skin tissue, peripheral blood mononuclear cells and serum of the psoriasis experimental group (P < 0.01). After treatment, the expression of miR-155 and miR-146a in peripheral blood mononuclear cells and serum decreased (P < 0.05). Conclusions: The significantly increased levels of miR-155 and miR-146a in psoriasis samples from different sources may mediate the immune mechanism involved in the activity process of psoriasis.